Skip to Main Content
Contribute Try STAT+ Today

Top of the morning to you, and a fine one it is. Clear blue skies and delicious cool breezes are enveloping the sunny Pharmalot campus, where the short person is sleeping in and the official mascot is futilely chasing bunnies and squirrels bounding across the grounds. Such scenes are best enjoyed with a cup of stimulation. So please join as we lean in to another busy day. On that note, here are a few items of interest. We hope your day goes well, and do keep us in mind if something juicy occurs. …

Drug makers partnered with the U.S. government are on track to begin manufacturing a Covid-19 vaccine by the end of the summer, and aim to deliver 300 million doses by early 2021, CNBC says. The manufacturing process is already underway, although it is not clear which, if any, vaccine will work. The Trump administration helped finance development of four vaccines so far though Operation Warp Speed and gave grants to companies including Johnson & Johnson (JNJ), Moderna (MRNA), AstraZeneca (AZN), and Novovax (NVAX).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.